Syrowatka, A., Song, W., Amato, M. G., Foer, D., Edrees, H., Co, Z., . . . Bates, D. W. (2022). Key use cases for artificial intelligence to reduce the frequency of adverse drug events: A scoping review. The Lancet. Digital health, 4(2), e137-e148. https://doi.org/10.1016/S2589-7500(21)00229-6
Citace podle Chicago (17th ed.)Syrowatka, Ania, et al. "Key Use Cases for Artificial Intelligence to Reduce the Frequency of Adverse Drug Events: A Scoping Review." The Lancet. Digital Health 4, no. 2 (2022): e137-e148. https://doi.org/10.1016/S2589-7500(21)00229-6.
Citace podle MLA (9th ed.)Syrowatka, Ania, et al. "Key Use Cases for Artificial Intelligence to Reduce the Frequency of Adverse Drug Events: A Scoping Review." The Lancet. Digital Health, vol. 4, no. 2, 2022, pp. e137-e148, https://doi.org/10.1016/S2589-7500(21)00229-6.